{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:41:20Z","timestamp":1792557680321,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Americas"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.lana.2024.100866","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T13:44:23Z","timestamp":1724939063000},"page":"100866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Venous thromboembolism prevention program implementation in a community oncology practice: a cohort study"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7077-1842","authenticated-orcid":false,"given":"Steven","family":"Ades","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonatan","family":"Resnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlyn","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Libby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lana.2024.100866_bib1","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.lana.2024.100866_bib2","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.lana.2024.100866_bib3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.lana.2024.100866_bib4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12094-019-02263-z","article-title":"SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)","volume":"22","author":"Munoz Martin","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"10","key":"10.1016\/j.lana.2024.100866_bib5","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH","volume":"17","author":"Wang","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"issue":"8","key":"10.1016\/j.lana.2024.100866_bib6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.lana.2024.100866_bib7","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.lana.2024.100866_bib8","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1002\/onco.13569","article-title":"Prediction and prevention of cancer-associated thromboembolism","volume":"26","author":"Khorana","year":"2021","journal-title":"Oncol"},{"issue":"1","key":"10.1016\/j.lana.2024.100866_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100038","article-title":"Implementing guidelines to prevent cancer associated thrombosis: how can we do better?","volume":"7","author":"Ades","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"9","key":"10.1016\/j.lana.2024.100866_bib10","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1200\/JOP.19.00697","article-title":"Successful model for guideline implementation to prevent cancer-associated thrombosis: venous thromboembolism prevention in the ambulatory cancer clinic","volume":"16","author":"Holmes","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"5","key":"10.1016\/j.lana.2024.100866_bib11","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.sapharm.2017.05.015","article-title":"The TOronto ThromboProphylaxis patient safety initiative (TOPPS): a cluster randomised trial","volume":"13","author":"Diamantouros","year":"2017","journal-title":"Res Social Adm Pharm"},{"issue":"3","key":"10.1016\/j.lana.2024.100866_bib12","first-page":"1699","article-title":"Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist's impact on anticoagulant therapy","volume":"29","author":"Kandemir","year":"2021","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.lana.2024.100866_bib13","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1177\/10781552211004705","article-title":"Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre","volume":"27","author":"Pelletier","year":"2021","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"3","key":"10.1016\/j.lana.2024.100866_bib14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A\u00a0modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score","volume":"7","author":"Verso","year":"2012","journal-title":"Intern Emerg Med"},{"issue":"10","key":"10.1016\/j.lana.2024.100866_bib15","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lana.2024.100866_bib16","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1002\/onco.13596","article-title":"Update on guidelines for the management of cancer-associated thrombosis","volume":"26","author":"Streiff","year":"2021","journal-title":"Oncol"},{"issue":"1","key":"10.1016\/j.lana.2024.100866_bib17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/bloodadvances.2021005590","article-title":"The incidence of cancer-associated thrombosis is increasing over time","volume":"6","author":"Mahajan","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.lana.2024.100866_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.lana.2024.100866_bib19","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40199-019-00292-1","article-title":"The cost-effectiveness and cost-utility analysis of the use of enoxaparin compared with heparin for venous thromboembolism prophylaxis in medical inpatients in Iran","volume":"27","author":"Amirsadri","year":"2019","journal-title":"Daru"},{"key":"10.1016\/j.lana.2024.100866_bib20","article-title":"Oncologists' attitudes towards prophylaxis of cancer associated venous thromboembolism: a prospective, descriptive study","author":"Kandemir","year":"2021","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"7","key":"10.1016\/j.lana.2024.100866_bib21","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/rth2.12431","article-title":"Preventing venous thromboembolism in oncology practice: use of risk assessment and anticoagulation prophylaxis","volume":"4","author":"Martin","year":"2020","journal-title":"Res Pract Thromb Haemost"}],"container-title":["The Lancet Regional Health - Americas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X24001935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X24001935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:16:40Z","timestamp":1792556200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667193X24001935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":21,"alternative-id":["S2667193X24001935"],"URL":"https:\/\/doi.org\/10.1016\/j.lana.2024.100866","relation":{},"ISSN":["2667-193X"],"issn-type":[{"value":"2667-193X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venous thromboembolism prevention program implementation in a community oncology practice: a cohort study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Americas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lana.2024.100866","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100866"}}